115 results on '"Xie Q"'
Search Results
2. Sepsis in HBV associated decompensated cirrhosis: A comparison between SIRS (Sepsis-1) and qSOFA (Sepsis-3) based criteria
3. Peginterferon is superior to nucleos(t)ide analogues for reduction ofchronic hepatitis B-related hepatocellular carcinoma in patients with high-riskscore
4. Low serum HBsAg and HBV DNA predict response of peg-interferon addition to entecavir in HBeAg positive chronic hepatitis B
5. A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 240
6. The effect of PEG-IFN add on or switch to on HBsAg clearance in HBeAg- CHB patients recieving entecavir treatment
7. The level of hepatocyte death biomarkers correlates with severity and predicts early mortality in patients with acute decompensation with or without acute-on-chronic liver failure
8. Baseline and early on-treatment HBsAg level to predict HBsAg loss in nucleotide analog suppressed and HBeAg cleared chronic hepatitis B patients by switching to peginterferon alfa-2a: exploratory results of NEW SWITCH study
9. Sequential combination therapy with IFN, rhIL-2 and therapeutic vaccine enhanced HBsAg loss in entecavir-suppressed CHB patients (the Endeavor study): an interim analysis
10. Small ubiquitin-like modifier protein-specific protease 3 de-SUMOylates NR4A2 protein and controls lipid metabolism in non-alcoholic fatty liver disease
11. The role of bacterial infection (BI) in decompensated cirrhosis patients with or without acute-on-chronic liver failure (ACLF)
12. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin in Asian patients with genotype 1b chronic hepatitis C virus infection and compensated cirrhosis: ONYX-II post-treatment week 24 results
13. Hepatitis B virus associated cirrhotic acute decompensated patients with hepatic insults were a heterogeneous population which included Acute-on-chronic Liver Failure patients
14. A novel non-invasive Golgi protein 73 (GP73)-based model accurately diagnoses significant fibrosis in chronic liver disease
15. Development and validation of diagnostic and prognostic criteria for chronic hepatitis B-related acute-on-chronic liver failure
16. Addition of (pegylated) interferon to entecavir increases response in treatment naïve HBeAg-positive patients with chronic hepatitis B
17. Impact of hepatoprotective medications on the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in hepatitis C virus genotype lb-infected Asian patients with and without cirrhosis in the ONYX-I and -II studies
18. Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study
19. Critical Role of Hepatocyte Death in the Pathophysiology of Acute on Chronic Liver Failure: Association between the Extent of Hepatocyte Death and Types of Precipitating Event
20. Previous Interferon Treatment Failure is Associated with Avery Low Chance of Response to Peginterferon Retreatment in HBeAg-Positive Chronic Hepatitis B: Pooled Analysis of Two Randomized Trials
21. Sumo-Specific Protease 3 is an Important Regulator of Lipid Metabolism in Nonalcoholic Fatty Liver Disease
22. A Genotype-Specific Baseline Score to Predict Post-Treatment Response to Peginterferon Alfa-2a in HBeAg-Positive Patients with Hepatitis B Virus Genotype B or C Infection
23. HBeAg Seroconversion Rates after Five Years of Follow-Up in Patients Treated with Peginterferon Alfa-2a (40kd) in Neptune: Final Results of the Son of Neptune Long-Term Follow-Up Study
24. HBV Associated Cirrhotic Patients Meeting Apasl Acute-On-Chronic Liver Failure Criteria Have Heterogeneous Outcome and Short Term Survival Rate
25. Five-Year on-Treatment Systematically Monitoring of Dynamic Changes of Liver Stiffness Measurement with Transient Elastography Compared with Paired Liver Biopsies in a Randomized Controlled Trial in Chronic Hepatitis B Patients
26. SAT-221 - Sepsis in HBV associated decompensated cirrhosis: A comparison between SIRS (Sepsis-1) and qSOFA (Sepsis-3) based criteria
27. FRI-344 - A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 240
28. FRI-346 - Low serum HBsAg and HBV DNA predict response of peg-interferon addition to entecavir in HBeAg positive chronic hepatitis B
29. FRI-348 - Peginterferon is superior to nucleos(t)ide analogues for reduction ofchronic hepatitis B-related hepatocellular carcinoma in patients with high-riskscore
30. FRI-325 - Efficacy and safety of combination therapy with interferon and immunomodulators in entecavir-suppressed chronic hepatitis B patients (the endeavor study)
31. FRI-320 - The effect of PEG-IFN add on or switch to on HBsAg clearance in HBeAg- CHB patients recieving entecavir treatment
32. P0669 : Consolidation therapy with entecavir can prevent post-treatment HBsAg rebound in HBeAg-positive chronic hepatitis B patients treated with peginterferon alpha
33. O116 : Predictive value of baseline and on-treatment qHBsAg level in HBeAg positive CHB patients who switched from NUCs to pegylated interferon A-2A: A further analysis from new switch study
34. P0662 : 24 weeks of peginterferon may be as good as 48 weeks in HBeAg-positive genotype B patients with an early HBsAg response: Pooled analysis of two randomized trials
35. P0613 : Hepatitis B core related antigen may be a marker for immune control in HBeAg negative chronic hepatitis B infection
36. P0623 : A combination of hepatocyte death biomarker with the meld score improves predictive accuracy of prognosis in patients with hepatitis B virus related acute-on-chronic liver failure
37. P0948 : Upregulated expression of SENP3 plays an important role in the progression of non-alcoholic fatty liver disease
38. P1051 EVALUATION OF ESTIMATED GLOMERULAR FILTRATION RATE DURING CONTINUOUS 4-YEAR TREATMENT WITH TELBIVUDINE IN PATIENTS WITH BRIDGING FIBROSIS/CIRRHOSIS
39. P1067 RESPONSE-GUIDED PEGINTERFERON ALFA-2a (PegIFN alfa-2a) THERAPY IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B (CHB)
40. P1045 ESTIMATING THE PROBABILITY OF RESPONSE TO PEG-INTERFERON THERAPY IN HBeAg-POSITIVE CHRONIC HEPATITIS B: THE EPIC-B STUDY
41. P414 ASSESSMENT OF THE CHANGE IN ESTIMATED GLOMERULAR FILTRATION RATES IN TELBIVUDINE- OR LAMIVUDINE-BASED TRERAPY IN PATIENTS WITH CHRONIC HEPATITIS B
42. O3 ADDING PEGINTERFERON TO ENTECAVIR INCREASES RESPONSE RATES IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS: WEEK 96 RESULTS OF A GLOBAL MULTICENTER RANDOMISED TRIAL (ARES STUDY)
43. FRI-148 - HBeAg Seroconversion Rates after Five Years of Follow-Up in Patients Treated with Peginterferon Alfa-2a (40kd) in Neptune: Final Results of the Son of Neptune Long-Term Follow-Up Study
44. FRI-137 - Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study
45. FRI-134 - Previous Interferon Treatment Failure is Associated with Avery Low Chance of Response to Peginterferon Retreatment in HBeAg-Positive Chronic Hepatitis B: Pooled Analysis of Two Randomized Trials
46. FRI-117 - A Genotype-Specific Baseline Score to Predict Post-Treatment Response to Peginterferon Alfa-2a in HBeAg-Positive Patients with Hepatitis B Virus Genotype B or C Infection
47. THU-400 - Critical Role of Hepatocyte Death in the Pathophysiology of Acute on Chronic Liver Failure: Association between the Extent of Hepatocyte Death and Types of Precipitating Event
48. THU-349 - HBV Associated Cirrhotic Patients Meeting Apasl Acute-On-Chronic Liver Failure Criteria Have Heterogeneous Outcome and Short Term Survival Rate
49. LBP528 - Sumo-Specific Protease 3 is an Important Regulator of Lipid Metabolism in Nonalcoholic Fatty Liver Disease
50. 41 S-Collate COHORT ‘REAL-LIFE’ STUDY: EFFICACY AND SAFETY OF PEGINTERFERON alfa-2a (40KD) IN 1233 PATIENTS WITH CHRONIC HEPATITIS B ACCORDING TO ASIAN AND CAUCASIAN RACE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.